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Abstract
Background:  Only four out of 31 completed randomize d  c o n t r o l l e d  t r i a l s  ( R C T s )  o f  H I V
prevention strategies against sexual transmission have shown significant efficacy. Poor adherence
may have contributed to the lack of effect in some of these trials. In this paper we explore the
impact of various levels of adherence on measured efficacy within an RCT.
Analysis:  We used simple quantitative methods to illustrate the impact of various levels of
adherence on measured efficacy by assuming a uniform population in terms of sexual behavior and
the binomial model for the transmission probability per partnership.
At 100% adherence the measured efficacy within an RCT is a reasonable approximation of the true
biological efficacy. However, as adherence levels fall, the efficacy measured within a trial
substantially under-estimates the true biological efficacy. For example, at 60% adherence, the
measured efficacy can be less than half of the true biological efficacy.
Conclusion: Poor adherence during a trial can substantially reduce the power to detect an effect,
and improved methods of achieving and maintaining high adherence within trials are needed. There
are currently 12 ongoing HIV prevention trials, all but one of which require ongoing user-
adherence. Attention must be given to methods of maximizing adherence when piloting and
designing RCTs and HIV prevention programmes.
Background
Recent randomized controlled trials (RCT) of herpes sup-
pressive therapy [1,2], female diaphragms and gel in addi-
tion to male condoms (the Methods for Improving
Reproductive Health in Africa, or MIRA trial) [3], and an
adenovirus-vectored HIV vaccine [4] have failed to show
an impact on HIV acquisition. These disappointing find-
ings contribute to a total of 31 completed RCTs with HIV
incidence as a primary outcome for sexual transmission
(Table 1), of which only four have shown a statistically
significant reduction in new HIV infections [5-8].
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Multiple factors are likely to be responsible for the failure
of the trials to see a protective effect, including interven-
tions which are truly non-efficacious, trials which were
under-powered to detect an effect, and poor adherence to
the intervention under study. It is striking that the only
intervention for which multiple trials have shown efficacy
in preventing HIV is male circumcision [5-7], a non-
reversible surgical procedure for which post-intervention
'adherence' is 100%. In contrast, some of the recent RCTs
of other interventions have suggested that poor adherence
may have contributed to the lack of effect [1,3].
In this paper, we use simple quantitative methods to
explore the impact of various levels of adherence on
observed efficacy in randomized controlled trials, and dis-
cuss the implications for designing future HIV interven-
tion trials.
Analysis
Methods
The impact of adherence in an RCT for an intervention
with different levels of efficacy was calculated by linking
the risk per sexual exposure to the cumulative risk calcu-
lated in longitudinal trials using simplifying assumptions
[9]. We assume a uniform population in terms of sexual
behavior and the binomial model for the transmission
probability per partnership [10]. These simplifying
assumptions give illustrative results of the effect of varying
adherence within the population on measured efficacy
within a RCT.
In the control arm, the probability of transmission per
partnership during the trial is
zControl = 1 - (1 - p)n*τ
Table 1: Randomised controlled trials of HIV prevention with HIV incidence as an outcome for sexual transmission
Intervention Individual or cluster 
randomization
RCTs completed or 
stopped
RCTs showing efficacy RCTs ongoing
Individual 2 0 0
[3,24]
Behavior change (abstinence/delay, 
Cluster 5 0 2
[15,25-28] [29,30]
Male Circumcision Individual 4 1 30
[5-7,31] [5-7]
Microbicides Individual 9 0 3
[32-40] [41-43]
Oral pre-exposure prophylaxis 
(PrEP)
Individual 1 0 4
[35] [44-47]
HIV Treatment Individual 0 0 1
[48]
Individual 3 0 1
[1,2,14] [49]
STI Treatment
Cluster 4 1 0
[8,15,16,50] [8]
HIV Vaccines Individual 4 0 1
[4,51-53] [54]
All Interventions 312 41 2
1 The trial which did not show efficacy was of the impact of male circumcision on female HIV acquisition
2 Total = 31 trials because study [15] is shown twice, under behavior change and STI treatmentEmerging Themes in Epidemiology 2008, 5:8 http://www.ete-online.com/content/5/1/8
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and that for the intervention arm is given by
Here, p = 0.0015 is the average HIV transmission probabil-
ity per coital act over all HIV stages for vaginal intercourse
[11], p = 0.0082 for receptive anal intercourse [12], n = 10
is the frequency of coital acts per month [11], and τ is the
average duration of the trial follow-up (here assumed to
be 18 months). The term EffInt is the biological efficacy of
the intervention under study in reducing HIV transmis-
sion probability per coital act, and fAdh is the mean adher-
ence level achieved in the trial (i.e. fraction of coital acts
protected by the intervention).
Then the risk ratio (RR) is given by
and EffMeasured = 1 - RR is interpreted as the "measured effi-
cacy" of the intervention during the trial.
Results
Figure 1 shows the measured efficacy within the trial
(EffMeasured = 1 - RR) as a function of mean adherence level
for interventions with true biological efficacy EffInt  of
25%, 50% and 75% respectively. At 100% adherence and
vaginal intercourse as the mode of transmission (Figure
1A), the measured efficacy is close to the true biological
efficacy (EffMeasured of 23%, 47% and 72% respectively
compared to EffInt of 25%, 50% and 75%). However, at
lower adherence levels, the measured efficacy within the
trial increasingly underestimates the true biological effi-
cacy of the intervention. For example, when adherence is
80%, the measured efficacy is considerably lower than the
true efficacy (EffMeasured of 18%, 37% and 57% respectively
compared to EffInt of 25%, 50% and 75%). At adherence
of 60%, the measured efficacy is just over half of the true
efficacy. The absolute impact of adherence is stronger for
interventions with relatively greater true biological effi-
cacy. An extension of this model using variable adherence
gave similar results (results not shown).
Similar results also hold for an intervention targeting
unprotected receptive anal intercourse (Figure 1B). The
measured efficacy here further underestimates the true
biological efficacy even at full adherence. The measured
efficacy is 13%, 32% and 60% respectively at 100% adher-
ence compared to EffInt of 25%, 50% and 75%. At 80%
adherence, the measured efficacy is 10%, 24% and 42%;
and at 60% adherence, it is 7%, 16% and 28% respec-
tively.
Discussion
The mean level of adherence achieved during an RCT
affects the measured efficacy of the intervention, and as
adherence falls, the measured efficacy will increasingly
under-estimate the true biological efficacy. The main
implications of this finding are that trials need to be pow-
ered to detect this smaller measured efficacy rather than
the true biological efficacy, and that methods to maximize
adherence within trials are urgently needed.
Many HIV prevention strategies rely on good levels of
adherence. To our knowledge, 31 RCTs have reported
results, of which 7 were behavioural interventions and 24
were primarily biomedical (Table 1). The behavioural
interventions include voluntary counseling and testing,
and educational interventions to promote abstinence,
reduce number of sexual partners, and increase use of
male condoms and female diaphragms. All of these rely
on ongoing user-adherence. None of the behavioural
RCTs found a significantly reduced risk of HIV acquisi-
tion. This may be partly due to truly ineffective interven-
tions, low power (due for example, to under-estimates of
HIV incidence, higher than expected loss to follow-up, or
effective interventions in the control arm), and difficulty
in achieving sustained, consistent behaviour change i.e.
poor adherence.
Biomedical interventions against HIV acquisition include
male circumcision, vaginal microbicides, oral pre-expo-
sure prophylaxis (PrEP), STI treatment and HIV vaccines.
The only one of these for which there has been consistent
efficacy in multiple trials is male circumcision in hetero-
sexual men. These trial results were striking both in the
magnitude of effect (summary efficacy 58%, 95% CI
43%–69%) which led to all 3 trials being halted early, and
also in the consistency of the results across trials and with
a previous meta-analysis of observational studies [13].
One plausible reason for the strong, consistent impact of
male circumcision on HIV acquisition is the in-built
100% 'adherence' of foreskin removal. Other biomedical
interventions, such as treatment of bacterial STDs, also
have the potential for substantial efficacy based on obser-
vational studies but only one of these RCTs afforded sig-
nificant protection against HIV acquisition [8,14-16].
Reasons for the inconsistent results of the bacterial STD
treatment trials have been widely discussed [17-20] and
include poor adherence to the intervention as well as
other factors such as the stage of the epidemic and preva-
lence of curable STDs in the trial population.
The importance of adherence is also suggested by the
MIRA trial, and one of the HSV-2 suppressive therapy tri-
als [1,3]. In the MIRA trial, participants in the intervention
arm were asked to insert a diaphragm and use a lubricant
gel before each coital act. In the HSV suppressive therapy
zp E f f p
nf nf
Intervention Int
Adh Adh =− − () −− () ∗ ()
∗∗ − () ∗∗
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Impact of partial adherence in randomized controlled trials Figure 1
Impact of partial adherence in randomized controlled trials. The measured efficacy (EffMeasured = 1 - RR) of an HIV pre-
vention intervention as a function of mean adherence level in a trial with actual biological efficacy per sexual act of EffInt = 25%, 
50% or 75% respectively. Panel A shows the results assuming vaginal intercourse as the mode of transmission and panel B 
shows the results assuming receptive anal intercourse as the mode of transmission.
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trials, women were asked to take two tablets of acyclovir
daily for up to 30 months. However, it is not clear whether
suboptimal adherence was one of the factors contributing
to the lack of efficacy. The median estimated adherence in
the two trials was 90–94%, but was difficult to verify due
to missing visits and reliance on self-report. It is possible
that adherence was not the main problem in these trials,
but rather that the drug or dosage used was insufficient to
switch off the frequent subclinical HSV reactivations. In
the Mwanza trial [1], there was little impact on detection
of genital HSV, again suggesting suboptimal adherence
overall, although the trial was not powered to measure an
impact on this endpoint. In the MIRA trial [3], there was
some evidence of impact among those women reporting
high levels of adherence, and suboptimal adherence is
suggested by the annual incidence of first pregnancy being
similar in both intervention and control groups (13%),
and consistent with the reported rates of pregnancy in
these populations (13.7% in Zimbabwe in 2005–2006
[21] and 10.0% in South Africa in 1998 [22]). Moreover,
the similar HIV incidence rates in both arms for each site,
and across each pre-defined baseline subgroup in the trial
may suggest that poor adherence was common in differ-
ent sites.
Methods of achieving and maintaining high adherence
both within trial and general populations must be a
research priority. To our knowledge, there are currently 12
ongoing HIV prevention trials, examining a range of inter-
ventions including community-based HIV voluntary
counseling and testing, vaginal microbicides, oral PrEP,
herpes therapy, and an HIV vaccine (Table 1). All of these
interventions, except an HIV vaccine, require ongoing
user-adherence. Consistent use of pharmaceutical inter-
ventions such as, oral PrEP or vaginal microbicides may
be easier to achieve than maintenance of behavioural
interventions, as suggested by experience with anti-retro-
viral therapy, for which adherence in sub-Saharan African
populations is high compared with that for condoms
[23]. However, adherence to these preventive interven-
tions is likely to be harder to maintain in uninfected indi-
viduals than adherence to therapeutic interventions, and
adherence at population-level will be lower than within
carefully monitored trials.
The importance of adherence in prevention trials has sev-
eral implications for the design and analysis of such trials.
Firstly, the anticipated levels of adherence must be taken
into account when designing a trial, as sub-optimal adher-
ence can dramatically reduce the power of the trial. Pilot
studies may be most useful in estimating realistic levels of
adherence, although it might be difficult to determine in
advance what level of adherence would be necessary to
achieve a meaningful impact. Secondly, every effort must
be made to measure adherence accurately in trials and val-
idation of self-reported adherence with biomarkers must
become a priority. Thirdly, studies should ideally have
adequate power to conduct sub-group analyses by adher-
ence level, to detect whether there is an intervention effect
among those with highest adherence in the absence of a
significant impact overall. However, to avoid biases, these
sub-group analyses would be best undertaken when the
controls receive a placebo, and in practice it is unlikely
that studies could be powered for such sub-group analy-
ses. Fourthly, simulation of trial outcome using mathe-
matical modeling at various levels of adherence can be
valuable in assessing the feasibility of the trials to answer
the intended research questions. Finally, when interpret-
ing trial results, it is important to consider that a null find-
ing does not necessarily indicate an ineffective
intervention, but may reflect poor adherence to the inter-
vention. Related to the issue of adherence within a trial is
adherence during roll-out of a prevention strategy, which
is likely to be lower than in controlled trials. Improved
measurement of adherence within trials will help pro-
grams estimate the effectiveness of a prevention strategy
during roll-out.
Conclusion
Poor adherence during a trial can substantially reduce the
power to detect an effect, and improved methods of
achieving and maintaining high adherence within trials
are needed. There are currently 12 ongoing HIV preven-
tion trials, all but one of which require ongoing user-
adherence. Maintaining good adherence to HIV preven-
tion strategies will continue to be pivotal in their success.
When designing and piloting both RCTs and HIV preven-
tion programs, every effort should be made to maximize
adherence.
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